Barely Significant
← all excerpts

Clinical and Immunological Factors Associated with Recommended Trough Levels of Adalimumab and Infliximab in Patients with Crohn's Disease.

Front Pharmacol · 2021 · PMC8762261 · PMID 35046819

Europe PMCDOI
1
hedged sentence
0.0062
closest p · 0.1× alpha
0.0062
boldest claim

The sentences

highly significantp = 0.0062actually significant
This association was highly significant in patients treated with intensified doses of adalimumab ( β = −0.1474; p = 0.0062) but weak and non-significant in patients treated with non-intensified doses ( β = −0.0193; p = 0.1973) as shown in Figure 3 .

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.